

## NON-RENOUNCEABLE ENTITLEMENT OFFER CLOSING DATE REMINDER

**Melbourne, Australia – 2 April 2026:** Percheron Therapeutics Limited (**ASX:PER**) wishes to remind Shareholders that the Non-Renounceable Entitlement Offer of fully paid ordinary shares announced on 16 March 2026, will close at **5pm (AEST) on Wednesday 8 April 2026**.

As announced on 16 March 2026 Percheron Therapeutics is undertaking a pro-rata non-renounceable offer of new fully paid ordinary shares (**New Shares**) under which Eligible Shareholders (defined below) will be offered two (2) New Shares for every five (5) existing Shares held at 7.00pm (AEDT) on Friday, 20 March 2026 (**Record Date**) at an issue price of \$0.005 per New Share (**Entitlement Offer**). Participants in the Entitlement Offer will also be issued one (1) free-attaching unlisted option for every two (2) New Shares subscribed for and issued (**New Options**). The New Options will expire two years from the date of issue and have an exercise price of \$0.01 each.

Any New Shares and New Options not validly subscribed for pursuant to the Entitlement Offer will be offered to investors for subscription under a separate offer (**Shortfall Offer**). Eligible Shareholders who have applied for their entitlement in full (and other investors determined by the Directors) may apply for additional New Shares and New Options (**Shortfall Securities**) under the Shortfall Offer, subject at all times to the Directors' discretion to scale back applications under the Shortfall Offer and otherwise in accordance with the allocation policy set out in the Prospectus lodged with ASIC on 16 March 2026. The Shortfall Securities will be offered on the same terms as the New Shares and New Options to be issued under the Entitlement Offer.

Eligible shareholders, being holders of fully paid ordinary shares in the Company as at the Record Date with a registered address in Australia, New Zealand, Singapore, Hong Kong and the United Kingdom (**Eligible Shareholders**) were sent correspondence on Tuesday 24 March 2026 containing instructions on how to view and download a copy of the Prospectus and Entitlement and Acceptance Form.

Eligible Shareholders that have not received the correspondence and would like to participate in the Entitlement Offer should immediately contact the Company Secretary Ms Deborah Ambrosini via email at [deborah.ambrosini@percherontx.com](mailto:deborah.ambrosini@percherontx.com) or by phone on 61 411 828 748.

---

## **About Percheron Therapeutics Limited**

Percheron Therapeutics Limited [ASX: PER | US OTC: PERCF] is a publicly listed biotechnology company focused on the development and commercialisation of novel therapies for oncology and rare diseases. The company's lead program is HMBD-002, a monoclonal antibody targeting the immune checkpoint regulator, VISTA. HMBD-002 has completed a phase I clinical trial in patients with advanced cancer, which has shown the drug to be generally safe and well tolerated, and Percheron aims to commence further clinical trials in CY2026. For further information, please see our website at [www.PercheronTx.com](http://www.PercheronTx.com), or email [info@PercheronTx.com](mailto:info@PercheronTx.com).

*This announcement has been authorised for release to the Australian Securities Exchange  
by the Board of Directors.*

---